EVOBRUTINIB TREATMENT REDUCES THE DAMAGE TO THE CNS AND INCREASES THE NUMBER OF CLASSICAL DENDRITIC CELLS IN EXPERIMENTAL MULTIPLE SCLEROSIS

• Mari Paz Serrano-Regal,
• Leticia Calahorra,
• Inmaculada Alonso-García,
• Ursula Boschert,
• Philipp Haselmayer,
• María Cristina Ortega,
• Isabel Machin-Diaz,
• Celia Camacho-Toledano,
• Jennifer García-Arocha,
• Diego Clemente

Affiliations

Mari Paz Serrano-Regal

Hospital Nacional de Parapléjicos, Neuroimmuno-repair Group., Toledo, Spain

Leticia Calahorra

Hospital Nacional de Parapléjicos, Neuroimmuno-repair Group., Toledo, Spain

Inmaculada Alonso-García

Hospital Nacional de Parapléjicos, Neuroimmuno-repair Group., Toledo, Spain

Ursula Boschert

Merck KGaA, Ares Trading Sa, Eysins, Switzerland

Philipp Haselmayer

Merck KGaA, Immunology, Darmstadt, Germany

María Cristina Ortega

Hospital Nacional de Parapléjicos, Neuroimmuno-repair Group., Toledo, Spain; Centro de investigación Biomédica en Red-Enfermedades Neurodegenerativas (CIBERNED), Neuroimmuno-repair Group, Madrid, Spain

Isabel Machin-Diaz

Hospital Nacional de Parapléjicos, Neuroimmuno-repair Group., Toledo, Spain; Centro de investigación Biomédica en Red-Enfermedades Neurodegenerativas (CIBERNED), Neuroimmuno-repair Group, Madrid, Spain

Celia Camacho-Toledano

Hospital Nacional de Parapléjicos, Neuroimmuno-repair Group., Toledo, Spain; Centro de investigación Biomédica en Red-Enfermedades Neurodegenerativas (CIBERNED), Neuroimmuno-repair Group, Madrid, Spain

Jennifer García-Arocha

Hospital Nacional de Parapléjicos, Neuroimmuno-repair Group., Toledo, Spain

Diego Clemente

Hospital Nacional de Parapléjicos, Neuroimmuno-repair Group., Toledo, Spain; Centro de investigación Biomédica en Red-Enfermedades Neurodegenerativas (CIBERNED), Neuroimmuno-repair Group, Madrid, Spain